Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study

2016 ◽  
Vol 24 (2) ◽  
pp. 151-156 ◽  
Author(s):  
Tom Feng ◽  
Lauren E Howard ◽  
Adriana C Vidal ◽  
Daniel M Moreira ◽  
Ramiro Castro-Santamaria ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Serum Cholesterol ◽  
Lower Urinary Tract ◽  
Urinary Tract Symptoms ◽  
Events Study ◽  
Lower Urinary

scholarly journals MP35-13 SERUM CHOLESTEROL AND RISK OF LOWER URINARY TRACT SYMPTOMS PROGRESSION: RESULTS FROM THE REDUCE STUDY

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Tom Feng ◽  
Lauren Howard ◽  
Adriana Vidal ◽  
Daniel Moreira ◽  
Ramiro Castro-Santamaria ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Serum Cholesterol ◽  
Lower Urinary Tract ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals The Effect of Benign Lower Urinary Tract Symptoms on Subsequent Prostate Cancer Testing and Diagnosis

2013 ◽  
Vol 63 (6) ◽  
pp. 1021-1027 ◽  
Author(s):  
Christopher J. Weight ◽  
Simon P. Kim ◽  
Debra J. Jacobson ◽  
Michaela E. McGree ◽  
Stephen A. Boorjian ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Alexandre Peltier ◽  
Fouad Aoun ◽  
Vincent De Ruyter ◽  
Patrick Cabri ◽  
Roland Van Velthoven
Keyword(s):  
Prostate Cancer ◽  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Metastatic Prostate Cancer ◽  
Symptom Relief ◽  
Locally Advanced ◽  
Open Label ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

This prospective, noninterventional, open-label, multicentre, Belgian study assessed the prevalence of moderate to severe lower urinary tract symptoms (LUTS) in patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin therapy and its effects on LUTS were evaluated focusing on symptom relief and changes in quality of life (QOL) related to urinary symptoms (November 2006 to May 2010). Inclusion criteria were age >18 years, histologically confirmed advanced or metastatic prostate cancer, and life expectancy ≥12 months. Exclusion criteria were treatment with any LHRH analogue within the last 6 months or any other investigational agent within the last 3 months before study entry. Patients who received one or more triptorelin doses and had one or more efficacy assessments were evaluated. In total, 325 patients were included with a median age of 74 years (50 to 95 years). Mean age at first diagnosis was73±8years. Moderate (IPSS 8–19) to severe (IPSS ≥ 20) LUTS were observed in 62% of patients. Triptorelin reduced LUTS severity. This improvement was perceived within the first 24 weeks of treatment and was maintained after 48 weeks. A decrease in PSA level was also observed.

Sign in / Sign up

Export Citation Format

Share Document